Clinical Trial Update: Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study of RO4929097, a gamma-secretase inhibitor, in pediatric patients with relapsed or refractory solid tumors, CNS tumors, lymphoma, or T-cell leukemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Atypical Teratoid Rhabdoid Tumor
• Central Nervous System Germinoma
• Ependymoma
• Hodgkin Lymphoma
• Medulloblastoma
• Pineoblastoma
• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma | Phase 1 | Status: TERMINATED